Rosiglitazone Attenuates Liver Inflammation in a Rat Model of Nonalcoholic Steatohepatitis

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Digestive Diseases and Sciences

• Publication date

  2007-04-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10620-007-9756-xPMID 17436085
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rosiglitazone

  2012cited by this paper
• Liver‐directed overexpression of mitochondrial glycerol‐3‐phosphate acyltransferase results in hepatic steatosis, increased triacylglycerol secretion and reduced fatty acid oxidation

  2006cited by this paper
• Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial

  2004cited by this paper
• The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance.

  2004cited by this paper
• Oral glucose tolerance deteriorates in rats fed with methionine choline deficient diet.

  2004cited by this paper
• Antiinflammatory roles of peroxisome proliferator-activated receptor gamma in human alveolar macrophages.

  2004cited by this paper
• 587 The effect of rosiglitazone on methionine and choline deficient diet model of non-alcoholic steatohepatitis in rats

  2004cited by this paper
• Evidence for a potent antiinflammatory effect of rosiglitazone.

  2004cited by this paper
• Rapid reversal of hepatic steatosis, and reduction of muscle triglyceride, by rosiglitazone: MRI/S studies in Zucker fatty rats

  2003cited by this paper
• Rosiglitazone attenuates liver inflammation in a rat model of non-alcoholic steatohepatitis

  2003cited by this paper
• Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment in normal range weight and moderately obese type 2 diabetic patients.

  2003cited by this paper
• Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice.

  2003cited by this paper
• Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis.

  2003cited by this paper
• Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR‐γ ligand rosiglitazone

  2003cited by this paper
• Metformin in non-alcoholic steatohepatitis.

  2002cited by this paper
• Metformin in non-alcoholic steatohepatitis.

  2001cited by this paper
• A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

  2001cited by this paper
• Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.

  2001cited by this paper
• Hepatic stellate cell activation occurs in nonalcoholic steatohepatitis.

  2001cited by this paper
• Different kinds of reactive oxygen and nitrogen species were detected in colon and breast tumors.

  2001cited by this paper
• Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration

  2000cited by this paper
• Metformin reverses fatty liver disease in obese, leptin-deficient mice

  2000cited by this paper
• Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Th1-like response in chronic hepatitis C.

  1999cited by this paper
• Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions

  1999influential reference
• The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation.

  1998cited by this paper
• Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

  1998cited by this paper
• The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation

  1998cited by this paper
• PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines.

  1998cited by this paper
• Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report

  1998cited by this paper
• Steatohepatitis: a tale of two "hits"?

  1998cited by this paper
• Helicobacter pylori stimulates antral mucosal reactive oxygen metabolite production in vivo.

  1994cited by this paper
• Assay for blood plasma or serum.

  1984cited by this paper

• Rosiglitazone Ameliorates Adverse Effects of High-Fat Diet in Largemouth Bass (Micropterus salmoides): Modulation of Lipid Metabolism, Antioxidant Capacity, Inflammatory Response, and Gut Microbiota

  2025cites this paper
• Comparison of efficacy of anti-diabetics on non-diabetic NAFLD: A network meta-analysis

  2023cites this paper
• Adverse Maternal Environments Perturb Hepatic DNA Methylome and Transcriptome Prior to the Adult-Onset Non-Alcoholic Fatty Liver Disease in Mouse Offspring

  2023cites this paper
• The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease

  2023cites this paper
• Production, Exacerbating Effect, and EV-Mediated Transcription of Hepatic CCN2 in NASH: Implications for Diagnosis and Therapy of NASH Fibrosis

  2023cites this paper
• Inhibition effect of PPAR-γ signaling on mast cell-mediated allergic inflammation through down-regulation of PAK1/ NF-κB activation.

  2022cites this paper
• Elastographic liver evaluation of Katukyadi churna in the management of Non-Alcoholic Steatohepatitis (NASH) – A single arm clinical trial.

  2021cites this paper
• Si-Wei-Qing-Gan-Tang Improves Non-Alcoholic Steatohepatitis by Modulating the Nuclear Factor-κB Signal Pathway and Autophagy in Methionine and Choline Deficient Diet-Fed Rats

  2020cites this paper
• Rosiglitazone ameliorates bile duct ligation-induced liver fibrosis by down-regulating NF-κB-TNF-α signaling pathway in a PPARγ-dependent manner.

  2019cites this paper
• Alpha-tocopherol in intravenous lipid emulsions imparts hepatic protection in a murine model of hepatosteatosis induced by the enteral administration of a parenteral nutrition solution

  2019cites this paper
• Histopathological changes and onset of severe hepatic steatosis in rats fed a choline-free diet

  2018cites this paper
• Effect of Phyllanthus emblica L. fruit on methionine and choline-deficiency diet-induced nonalcoholic steatohepatitis

  2018cites this paper
• Metabolomic Profiling Distinction of Human Nonalcoholic Fatty Liver Disease Progression from a Common Rat Model

  2017cites this paper
• Enhanced prevention of progression of non alcoholic fatty liver to steatohepatitis by incorporating pumpkin seed oil in nanoemulsions

  2017cites this paper
• Protective effect of rosiglitazone against acetaminophen-induced acute liver injury is associated with down-regulation of hepatic NADPH oxidases.

  2017cites this paper
• Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine N-methyltransferase-deficient mice.

  2016cites this paper
• Ameliorative Potential of Thiazolidinediones and Statins on Experimentally Induced Non-Alcoholic Steatohepatitis

  2014cites this paper
• Hesperidin protects against cyclophosphamide-induced hepatotoxicity by upregulation of PPARγ and abrogation of oxidative stress and inflammation.

  2014cites this paper
• Experimental models of non-alcoholic fatty liver disease in rats.

  2014cites this paper
• Polyphenols and Flavonoids in Controlling Non-Alcoholic Steatohepatitis

  2014cites this paper
• Combination of vildagliptin and rosiglitazone ameliorates nonalcoholic fatty liver disease in C57BL/6 mice

  2014cites this paper
• Chromium Picolinate and Rosiglitazone Improve Biochemical Derangement in a Rat Model of Insulin Resistance: Role of TNF-a and Leptin

  2013cites this paper
• PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs

  2012cites this paper
• Improvement of abnormal liver enzymes after rosiglitazone treatment in Chinese type 2 diabetes

  2012cites this paper
• Non-alcoholic steatohepatitis: an overview including treatments with herbals as alternative therapeutics

  2012cites this paper
• Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside

  2012cites this paper
• Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice

  2011cites this paper
• Rat model of nonalcoholic steatohepatitis created by methionine and choline deficiency: biochemical and histological analyses

  2011cites this paper
• Prevention of sodium valproate-induced hepatotoxicity by curcumin, rosiglitazone and N-acetylcysteine in rats

  2010cites this paper
• The effects of L-tryptophan and melatonin on selected biochemical parameters in patients with steatohepatitis.

  2010cites this paper
• Hepatic effects of rosiglitazone in rats with the metabolic syndrome.

  2010cites this paper
• Melatonin ameliorates methionine‐ and choline‐deficient diet‐induced nonalcoholic steatohepatitis in rats

  2009cites this paper
• Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice

  2009cites this paper
• Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases.

  2008cites this paper
• Rosiglitazone Activates AMPK and Improves Non-Alcoholic Fatty Liver Disease in OLETF Rats

  2008cites this paper
• Prognosis and Therapy of Wernicke's Encephalopathy After Obesity Surgery

  2008cites this paper
• The adipocyte as an endocrine cell.

  2008cites this paper
• Increased Hepatic and Circulating Interleukin-6 Levels in Human Nonalcoholic Steatohepatitis

  2008cites this paper
• Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPARgamma) gene in inflammatory bowel disease.

  2008cites this paper
• Reply:

  2007cites this paper
• Effects of rosiglitazone on methionine‐choline deficient diet‐induced nonalcoholic steatohepatitis

  2007cites this paper